36.89
Harmony Biosciences Holdings Inc stock is traded at $36.89, with a volume of 474.41K.
It is down -2.84% in the last 24 hours and up +4.06% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$37.97
Open:
$38
24h Volume:
474.41K
Relative Volume:
0.81
Market Cap:
$2.12B
Revenue:
$681.88M
Net Income/Loss:
$122.63M
P/E Ratio:
17.48
EPS:
2.11
Net Cash Flow:
$220.18M
1W Performance:
-2.56%
1M Performance:
+4.06%
6M Performance:
+12.64%
1Y Performance:
+3.19%
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HRMY
Harmony Biosciences Holdings Inc
|
36.89 | 2.18B | 681.88M | 122.63M | 220.18M | 2.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-21-25 | Initiated | Truist | Buy |
Jul-10-25 | Resumed | Goldman | Neutral |
Jun-02-25 | Resumed | Oppenheimer | Outperform |
Feb-11-25 | Initiated | Deutsche Bank | Buy |
Dec-17-24 | Initiated | H.C. Wainwright | Buy |
Oct-10-24 | Resumed | Raymond James | Outperform |
Sep-10-24 | Initiated | UBS | Buy |
Jun-21-24 | Initiated | Citigroup | Buy |
Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
Sep-07-23 | Initiated | Berenberg | Buy |
Apr-20-23 | Initiated | BofA Securities | Neutral |
Oct-14-22 | Upgrade | Janney | Neutral → Buy |
Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
Jul-07-22 | Initiated | Mizuho | Buy |
Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
Dec-01-21 | Initiated | Oppenheimer | Outperform |
Nov-04-21 | Initiated | Raymond James | Outperform |
Sep-23-21 | Initiated | Needham | Buy |
Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
Sep-14-20 | Initiated | Goldman | Neutral |
Sep-14-20 | Initiated | Jefferies | Buy |
Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Is Harmony Biosciences Holdings Inc. building a consolidation baseMarket Performance Summary & Verified Momentum Stock Alerts - Newser
Key metrics from Harmony Biosciences Holdings Inc.’s quarterly dataWeekly Risk Report & Consistent Income Trade Ideas - Newser
Will Harmony Biosciences Holdings Inc. bounce back from current supportWeekly Gains Report & Smart Swing Trading Techniques - Newser
Using RSI to spot recovery in Harmony Biosciences Holdings Inc.Trade Volume Summary & Consistent Profit Alerts - Newser
Does Harmony Biosciences Holdings Inc. fit your quant trading modelQuarterly Investment Review & Long-Term Safe Return Strategies - Newser
Momentum divergence signals in Harmony Biosciences Holdings Inc. chartSwing Trade & Fast Gain Stock Tips - Newser
Tools to assess Harmony Biosciences Holdings Inc.’s risk profileJuly 2025 Fed Impact & Real-Time Market Trend Scan - Newser
Visual analytics tools that track Harmony Biosciences Holdings Inc. performanceQuarterly Growth Report & Capital Efficient Trading Techniques - Newser
Backtesting results for Harmony Biosciences Holdings Inc. trading strategiesGold Moves & Real-Time Chart Breakout Alerts - Newser
How sentiment analysis helps forecast Harmony Biosciences Holdings Inc.Rate Cut & Long-Term Capital Growth Strategies - Newser
Chart overlay techniques for tracking Harmony Biosciences Holdings Inc.Market Volume Summary & Fast Moving Trade Plans - Newser
Should you wait for a breakout in Harmony Biosciences Holdings Inc.New Guidance & Free Technical Pattern Based Buy Signals - Newser
Heatmap analysis for Harmony Biosciences Holdings Inc. and competitorsMarket Trend Report & Community Verified Watchlist Alerts - Newser
Harmony Biosciences Holdings Inc. stock outlook for YEARShort Setup & Real-Time Market Trend Scan - Newser
Is Harmony Biosciences Holdings Inc. stock reversal real or fakeJuly 2025 EndofMonth & Real-Time Market Sentiment Alerts - Newser
Historical volatility pattern of Harmony Biosciences Holdings Inc. visualizedWeekly Gains Summary & Smart Investment Allocation Tips - Newser
Is this a good reentry point in Harmony Biosciences Holdings Inc.July 2025 Macro Moves & AI Forecasted Stock Moves - Newser
Custom strategy builders for tracking Harmony Biosciences Holdings Inc. - Newser
Precision BioSciences Inc. stock daily chart insightsJuly 2025 Rallies & Safe Capital Allocation Plans - Newser
What institutional flow reveals about Harmony Biosciences Holdings Inc.Bond Market & Community Verified Watchlist Alerts - Newser
Harmony Biosciences Holdings, Inc. (HRMY) Expands WAKIX With FDA Nod for Prader-Willi - Yahoo Finance
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):